Trial Profile
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Autologous stem cell therapy; Busulfan; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Vincristine
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- Acronyms EE2012; Euro Ewing 2012
- 18 Apr 2024 Planned End Date changed from 30 Apr 2024 to 1 Sep 2024.
- 15 Jul 2022 Patient recruitment was completed on 30 Apr 2019
- 31 May 2020 Results of overall and subgroup analysis from EE2012 trial presented at the 56th Annual Meeting of the American Society of Clinical Oncology